Among childhood cancer survivors, increased stroke risk after cranial radiation therapy may be caused by radiation-induced arteriopathy, but limited data exist to support this hypothesis. Herein, we assess the timing and presence of cerebral arteriopathy identified by magnetic resonance angiography (MRA) after cranial radiation therapy in childhood brain tumor survivors. In a cohort of 115 pediatric brain tumor survivors, we performed chart abstraction and prospective annual follow-up to assess the presence of large vessel cerebral arteriopathy by MRA. We identified 10 patients with cerebral arteriopathy. The cumulative incidence of arteriopathy 5 years post-cranial radiation therapy was 5.4% (CI 0.6%-10%) and 10 years was 16% (CI 4.6%-26%). One patient had an arterial ischemic stroke 2.4 years post-cranial radiation therapy in the distribution of a radiation-induced stenotic artery. We conclude that large vessel arteriopathies can occur within a few years of cranial radiation therapy and can become apparent on MRA in under a year.
walls. Postcontrast enhancement features on vessel wall imaging are likely surrogates of inflammatory changes. 13, 14 Detection of arterial inflammation or atherosclerotic disease prior to the onset of overt arteriopathy may act as an early imaging marker of disease and could indicate the use of therapeutic interventions such as anti-inflammatory agents.
To address this important gap in understanding the effects of cranial radiation therapy on pediatric brain tumor survivors, we evaluated a series of patients with magnetic resonance angiography (MRA) and vessel wall imaging. We report the timing and cumulative incidence of radiationinduced cerebral arteriopathy.
Methods

Patient Characteristics
Patients are part of the ongoing Radiation Arteriopathy (RadArt) study, a multisite cohort study of childhood cancer survivors that began enrollment in 2011. 15 Patients of any age are recruited with the following inclusion criteria for case enrollment: radiation therapy to the brain or neck at age 21 years, survival >1 year after diagnosis, and ability to undergo MRI. Patients in the study are prospectively followed with the collection and central review of clinically obtained brain and cerebrovascular imaging that varies in frequency by institution. Participating institutions include University of California San Francisco (UCSF) Benioff Children's Hospitals in Oakland and San Francisco, Valley Children's Hospital in Madera, California, and Washington University/St. Louis Children's Hospital in St. Louis, Missouri.
This analysis is based on 154 eligible patients enrolled into RadArt between October 2011 and October 2015. Patients without MRI postcranial radiation therapy were excluded (n ¼ 39) (Figure 1 ). The final analysis included 115 of 154 eligible patients.
Data Collection
Trained research assistants used standardized data collection tools to perform chart abstraction. Data audits were performed to ensure internal consistency and correct data collection. We collected detailed demographic, clinical, and tumor-and radiation-related information for each subject. Variables extracted included age at initiation of cranial radiation therapy, radiation dose and field, sex, gender, race, presence of known genetic disorders, tumor type and location, surgical intervention, type of MRI, as well as presence of stroke symptoms. Chemotherapies were determined to be associated with vascular injury in cases where agents had previously reported risk for stroke or vasculitis. These chemotherapies included adriamycin, avastin, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, irinotecan, isotretinoin, methotrexate, and vorinostat. Patients were evaluated prospectively starting in October 2011 with scheduled interviews every 6 months to assess for presence of stroke symptoms. MRI prior to study enrollment was obtained if deemed clinically necessary per the providing physician, with the primary indication being routine screening for disease progression and vasculopathy following radiation therapy. Following study enrollment, participants received regular MRI, with most patients receiving an MRA annually. Total radiation dose was calculated as the highest dose delivered either as whole brain or focal boost radiation. The arteriopathy was determined to be in the field of radiation for focal radiation through comparison of tumor and arteriopathy location. MR angiography data were procured from outside institutions when available. Vessel wall imaging data were available only for subjects evaluated at UCSF Benioff Children's Hospital San Francisco.
Vessel Wall Imaging
Vessel wall imaging was performed using a 3D CUBE T1, a volumetric, variable flip angle fast spin echo sequence, on a 3-Tesla GE Discovery 750 MRI scanner. Image acquisition was performed with whole brain coverage prescribed with a sagittal volume using isotropic spatial resolution that permitted reformations in arbitrary planes. The imaging parameters were TR/TE ¼ 600 ms/8 ms; ETL ¼ 20; acceleration factor ¼ 3; and number of averages ¼ 1. The FOV was 200 Â 180 Â 120 mm 3 at a matrix of 256 Â 230 Â 140 for an acquired voxel volume of 0.8 Â 0.8 Â 0.8 mm 3 (scan time, 5 minutes 40 seconds). Images were acquired pre-and post-contrast with a single dose of gadolinium chelate (Gadavist).
Standard Protocol Approvals, Registrations, and Patient Consents
This study has local IRB approval for prospective and retrospective study of human subjects. Written informed consent, and assent when appropriate, was obtained for all patients or guardians of patients in the study.
MRI Evaluation
All MRA data were reviewed by a board-certified radiologist with certificate of additional qualification in neuroradiology (BT), blinded to patient identity and clinical characteristics. MRA data were evaluated for presence, number, and location of arterial stenosis or occlusion. Vascular abnormalities thought to represent congenital variants or compression by the tumor were not classified as arteriopathies. All arteriopathies identified were confirmed by secondary review (SM, HF). Previous scans were reviewed to determine the first radiographic appearance. When available, vessel-wall images were interpreted by study neuroradiologist (BT) for the presence or absence of arterial wall enhancement, thinning, or thickening. MRI was not performed according to a standardized protocol and differed according to the institution and year of origin.
Statistical Analysis
Chi-squared tests were used to determine differences between the sample of patients with and without arteriopathy. Kaplan-Meier survival analysis techniques were used to determine the cumulative incidence of radiographically defined arteriopathies. The primary outcome was time to first radiographic appearance of intracranial arteriopathy, calculated from the start of cranial radiation therapy to the date of first MRA with evidence of arteriopathy. Censoring criteria were date of first MRA with evidence of arteriopathy (the failure event) or last follow-up MRA without evidence of arteriopathy. Given that actual time to arteriopathy development cannot be known, we used detection date to calculate incidence rates.
Results
Patient Characteristics
For the 115 patients included in this analysis, the median age at time of cranial radiation therapy was 8.4 years (interquartile range [IQR], 5.0-11.7). Patients had a median follow-up time (defined as time from cranial radiation therapy to last MRA) of 4.6 years (IQR, 2.9-8.6). The median time from cranial radiation therapy to first MRA was 3.9 years (range, 0.04-26.1), and the median interval between MRA scans was 1.4 years (range, 0.16-15) ( Table 1 and Figure 2 ). Patients in our cohort received a median radiation dose of 54 Gy (IQR, 54-55.8). The percentage of patients with an arteriopathy and without an arteriopathy who were exposed to chemotherapy that is associated with vascular injury was 50% and 45%, respectively (P value, .92). None of the patients in the cohort had hypertension, diabetes mellitus, or hyperlipidemia prior to diagnosis and treatment.
Large Vessel Arteriopathy
In the cohort of 115 study participants, we identified 10 patients (8.7%) with a large vessel cerebral arteriopathy by MRA ( Figure 2 and Table 2 ). Baseline demographics of the patients with cerebral arteriopathy show that most were female (n ¼ 8, 80%) and carried a diagnosis of a low-grade glioma (n ¼ 4, 40%). Median age at time of cranial radiation therapy was 6.3 years (IQR, 4.5-8.5) compared to 9.0 years (IQR, 5.0-11.9) for those without an arteriopathy. All 10 patients received a total radiation dose greater than 50 Gy to the whole brain and/ or tumor bed. The radiation field for these patients included the circle of Willis and the involved arteries, though the exact dose to the region of arteriopathy could not be determined. Three of the 10 patients with arteriopathy received proton beam therapy, compared to only 1 of the 105 patients without arteriopathy. One patient within the arteriopathy group had neurofibromatosis type 1 (NF1), whereas there were 3 patients with NF1 in the nonaffected group. Five of the 10 patients with arteriopathy had moyamoya, with 4 displaying Suzuki stage 1 moyamoya with only narrowing of the distal ICA, whereas 1 patient had clear collateral formation (Tables 1 and 2 Of the patients with arteriopathies, 3 had a prior normal MRA for comparison. The remaining 7 patients' arteriopathies were found on first MRA. These arteriopathies were determined to be most consistent with a radiation-induced arteriopathy on the basis of focality of disease, localization to the radiation field and absence of other findings to suggest dissection, occlusive disease, or widespread vasculopathy. The median latency of arteriopathy diagnosis (defined as the time from cranial radiation therapy to first abnormal MRA) was 4.8 years post-cranial radiation therapy (IQR, 2.4-7.8) ( Table 2 ). The cumulative incidence of arteriopathy at 5 years following cranial radiation therapy was 5.4% (95% CI 0.6%-10%) and at 10 years was 16% (95% CI 4.6%-26%) (Figure 3) . Of the 3 patients with prior normal MRA data, 1 did not have regular imaging after cranial radiation therapy, resulting in a 12-year gap between the last normal MRA and the subsequent MRA with evidence of arteriopathy. The other 2 patients were found to have evidence of arteriopathy on imaging performed 9 and 10 months following their last prior normal MRA (Figure 2 ). For the patients with no prior normal MRA, the time to detection of arteriopathy ranged from 1.4 to 8.5 years post cranial radiation therapy.
Vessel Wall Imaging
Four of the subjects with an identified arteriopathy had vessel wall imaging performed, of which 3 had 3D images available for review. Patient 2 demonstrated a well-defined focal narrowing of the lumen of the right middle cerebral artery with eccentric thickening of the wall with more pronounced thickening on the inferior aspect of the artery. The lesion is best delineated on the postcontrast study where there is noticeable enhancement of the vessel wall (Figure 4 ). This lesion was identified on this patient's first vessel wall imaging, 1.4 years after identification of an arteriopathy in the same vessel. The 3 other subjects showed no other evidence of arterial wall abnormalities on vessel wall imaging.
Stroke
Two patients (2%) in the study population had a confirmed stroke that occurred following cranial radiation therapy. One patient had a hemorrhagic stroke, possibly secondary to a bleeding cavernous malformation, 6.6 years following cranial radiation therapy and had no evidence of arteriopathy on MRA. The other patient (patient 4) had an acute ischemic stroke 2.4 years following cranial radiation therapy. The stroke was in the distribution of the stenotic artery found on MRA (Table 2 ). This patient had subjective symptoms suggestive of transient ischemic attack (TIA) and eventually had a completed stroke event 11 days after the first TIA in the absence of prophylactic therapy. Following the stroke, this patient was started on aspirin and has been maintained on antiplatelet therapy since. One of the other 9 patients with arteriopathies experienced symptoms concerning for a TIA although a complex migraine disorder could not be excluded-prompting the MRA that identified the arteriopathy. The other 8 were identified with a routine screening MRA and have not reported symptoms concerning for cerebral ischemia. Of the 10 patients with arteriopathies, half of them have been started on prophylactic aspirin.
Discussion
In this multicenter prospective cohort study, we found that children treated with cranial radiation therapy for intracranial tumors are at the risk of developing a large vessel arteriopathy and that this radiation-induced arteriopathy can develop within the first years after completion of radiation therapy. Three of the 10 patients with arteriopathy were treated with proton beam therapy, although an association cannot be concluded. Despite the known risk of arteriopathy following cranial radiation therapy, our understanding of the cumulative incidence and association with stroke remains limited. [7] [8] [9] [10] [11] 17 We know that children with arteriopathy have increased risk for stroke and recurrent stroke, with a 5-year cumulative recurrence rate of 66%. 8, 9, 18 Several factors have limited our progress, including that dedicated vascular imaging is not routinely performed on a clinical basis. In our study population of patients evaluated with MRA, 1 in 20 patients developed an arteriopathy by 5 years following cranial radiation therapy. Two previous studies have reported on the cumulative incidence of arteriopathy following cranial radiation therapy, though they have looked only at moyamoya rather than other focal arteriopathies in the anterior, middle, and/or posterior cerebral arteries. They reported dramatically different values, with 1 study reporting the 7-year cumulative incidence to be 7% in a pediatric brain tumor population and the other reporting an 8-year cumulative incidence of 0.46% in a pediatric acute lymphoblastic leukemia population-a difference that might be attributed to the lower dose of cranial radiation therapy children with acute lymphoblastic leukemia receive. 8, 9 The reported cumulative incidence in our study is similar to what has been identified in the previous study using a brain tumor population. 9 The slightly higher cumulative incidence in this study is likely due to the use of MRA as dedicated vascular imaging and inclusion of all large vessel arteriopathies, not just moyamoya syndrome, which only accounts for 5 of the 10 subjects with arteriopathies in our data set.
Higher radiation doses have also been associated with an earlier time to intracranial arteriopathy in the pediatric brain tumor population. 9, 17 The majority of large vessel arteriopathies, including moyamoya, occur in the first 5 to 6 years following cranial radiation therapy. 7, 9, 17 Our study cohort had a latency time to detection of arteriopathy that was slightly longer, with the majority of patients being diagnosed by 7.8 years post-cranial radiation therapy. However, we suspect the true latency time to be shorter than 7.8 years since half of the patients with arteriopathies did not receive an MRA until 6 to 12 years following cranial radiation therapy. Additionally, we had a relatively low proportion of patients with NF1 compared to prior studies, a known risk factor for arteriopathies. 9 Despite this longer latency, our data show that arteriopathies can develop over the span of months following a normal MRA and in the absence of symptoms. This suggests that follow-up imaging every 6 to 12 months may be indicated to ensure prompt detection of arteriopathy.
Three of 10 patients who received proton beam therapy developed an arteriopathy, whereas only 1 of the 105 patients without arteriopathy had proton beam therapy. Additionally these 3 patients developed arteriopathies sooner than anticipated, with all of them diagnosed before the median latency time to detection of 4.8 years. Although there are limited data on the long-term vascular effects of proton beam therapy for brain tumors, there is a case report of moyamoya following proton beam radiation and evidence of radiation vasculopathy in the eyes following proton beam therapy for ocular metastases. 19, 20 Unfortunately, this study was not powered to determine a risk difference between the 2 radiation therapy modalities. In addition to proton beam therapy, there are data to suggest that children with brain tumors treated with brachytherapy may also be at an increased risk of developing vasculopathy. 21 These data in conjunction with concerns associated with proton beam therapy suggest that more research is needed to evaluate the risk of vasculopathy following other forms of radiation therapy.
We found 1 patient with a well-documented middle cerebral artery stenosis following cranial radiation therapy that had transient ischemic attacks followed by an acute ischemic stroke in the distribution of the affected vessel. This represents an example of a potential causal pathway that explains the known elevated risk of stroke and recurrent stroke in patients with arteriopathy. 1, [3] [4] [5] 22 The one patient's hemorrhagic stroke without evidence of arteriopathy may have been secondary to cavernous malformations that can hemorrhage at a rate of 2% per year, though there was no evidence of cavernous malformations on prior imaging. 23, 24 The absence of symptoms in the remaining 9 patients with arteriopathy indicates they have sufficient collateral blood flow or insufficient narrowing of the vessel. The subset of these 9 patients followed at Benioff Children's Hospital San Francisco are being monitored closely for symptoms suggestive of stroke, evaluated, and advised regarding atherosclerotic risk factors including hyperlipidemia, smoking, and hypertension. Five patients were started on prophylactic aspirin following identification of arteriopathy based on the recommendation of the treating team. We know that patients with arteriopathies could be at risk of developing a late-occurring stroke and may benefit from initiating atherosclerotic risk-reducing therapies. 3 To further our understanding of the underlying pathophysiology involved in the formation of large vessel arteriopathies, vessel wall imaging was attempted when possible to allow for direct characterization of pathologic changes of the vessel wall. Vessel wall imaging allows for direct visualization of postcontrast enhancement features that are putative surrogates of inflammatory changes, with some data to suggest these changes can be seen in adults with radiation-induced arteriopathy. 13, 25 We know that several animal studies have shown that radiation therapy leads to inflammatory changes in a dose-and timedependent manner. 26, 27 Using positron emission tomography / computed tomography imaging, evidence of radiationinduced inflammation has also been reported in neck vessels in adult head and neck cancer patients. 28 Although MRA studies (and indeed catheter-injected angiography studies) are valuable in delineating changes in the caliber of the vascular lumen, they provide little or no information on the status of the vessel wall. State-of-the-art vessel wall imaging studies can demonstrate the presence of vessel wall thickening and indicate whether the lesion is eccentric and whether it enhances postadministration of gadolinium-based agents. The presence of vessel wall thickening in the region of a cranial radiation therapy-induced arteriopathy, as shown for one of the subjects in this study, suggests imaging modalities such as vessel wall imaging may offer the promise of better understanding the clinical significance of a given lesion. To expand our understanding of the temporal relationship between vessel wall changes and arteriopathies, regular vessel wall imaging following cranial radiation therapy would be required.
The key limitations in our study include the inability to determine the exact time of arteriopathy formation, inconsistent availability of vessel wall imaging and the relatively short prospective follow-up period thus far. The presence of arteriopathy can only be determined at the time of imaging and the limited availability of prior normal MRA inhibits the ability to definitively state that the arteriopathies occurred following cranial radiation therapy and prevents accurate time-to-event analysis. Despite that limitation, we believe these arteriopathies to have developed following cranial radiation therapy since these patients had no other reason to have developed an arteriopathy. Because of the relatively short follow-up, we were not able to better assess an association between arteriopathy and stroke. Further, as proton beam therapy becomes more easily accessible, future studies will be significantly powered to determine if the risk of radiation-induced arteriopathy is influenced by the type of radiation beam.
Conclusion
We conclude that large vessel arteriopathies can occur within a few years of cranial radiation therapy and can become apparent on MRA in under a year and thus regular MRA screening may be warranted. A better understanding of the timing and mechanisms of arteriopathy formation is critical as it may present an opportunity for primary stroke prevention in the pediatric brain tumor survivor population.
Author Contributions
MN performed statistical analysis and interpretation of data and was the primary author of manuscript. EF, JT, KG, BDB, AB, DSam, DSal, BT, CH performed data collection. EF, D. Saloner, ER, CH edited the manuscript. KS, BT, JT, KG, DAHK, HF, and SM designed the study. KS, BT, DAHK, JC, BDB, DSal, HF, and SM performed data analysis. HF and SM wrote the manuscript.
